Follow‐Up of 3‐Year Luspatercept Treatment in a Transfused ß‐Thalassemia Patient. Bone Marrow: An Undervalued Iron Store
ABSTRACT Introduction Treatment with luspatercept may improve transfusion requirements in transfusion‐dependent thalassemia (TDT), but the improved erythroid maturation in the bone marrow influences body iron distribution. Case Report We report on sequential organ iron measurements in a TDT patient...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wiley
2025-12-01
|
| Cyfres: | eJHaem |
| Mynediad Ar-lein: | https://doi.org/10.1002/jha2.70193 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|